Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biologic dose reduction in psoriasis patients with stable low disease activity
NL-OMON24722Not yet recruiting
- Sponsor
- Radboudumc
- Start
- Jan 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of adalimumab, etanercept and ustekinumab in plaque psoriasis (3 arms), sponsored by Radboudumc. Primary endpoint: Psoriasis Area and Severity Index at 12 months. Planned start Jan 2016; status: not yet recruiting.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON24722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24722.